LENZ Therapeutics (LENZ) Operating Margin (2025 - 2026)

LENZ Therapeutics (LENZ) reported Operating Margin of 2321.67% for Q1 2026, down 854.51% quarter-over-quarter from 307.7% in Q4 2025.

LENZ Therapeutics (LENZ) Operating Margin (2025 - 2026) Analysis & Trends

LENZ Therapeutics (LENZ) has 2 years of Operating Margin data on file, last reported at 2321.67% in Q1 2026.

Operating Margin for Q1 2026 came in at 2321.67%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 1714.85% (changed N/A YoY), and the FY2025 annual result was 1822.76%, changed N/A from the prior year.
Operating Margin declined to 2321.67% in Q1 2026 per LENZ's latest filing, from 307.7% in the prior quarter.
Over five years, Operating Margin peaked at 307.7% in Q4 2025 and troughed at 2321.67% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Operating Margin (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	-6.43%
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	38.10%
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	LENZ Therapeutics	213.20 Mn	213.20 Mn	825,000.00	-2,321.67%

Download Data